Company news

CytoSorbents Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytoSorbents Rights Offering Begins

December 22, 2024

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

December 11, 2024

CytoSorbents Announces Rights Offering

December 8, 2024

CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference

November 25, 2024

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

November 10, 2024

CytoSorbents Reports Third Quarter 2024 Financial and Operational Results

November 6, 2024

CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification

November 3, 2024

FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review

October 21, 2024

CytoSorbents to Report Third Quarter 2024 Operating and Financial Results

October 16, 2024

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

September 30, 2024

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

August 26, 2024

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2024

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

August 12, 2024

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

August 12, 2024

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

August 6, 2024

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

July 31, 2024

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

July 29, 2024

CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

July 16, 2024

CytoSorbents Secures $20 Million Credit Facility

July 1, 2024

CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan

June 23, 2024

CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union

June 12, 2024

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting

June 4, 2024

CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract

June 3, 2024

CytoSorbents Reports First Quarter 2024 Results

May 8, 2024

CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

May 1, 2024

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

April 25, 2024

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

April 16, 2024

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

March 13, 2024

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

March 5, 2024

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

February 7, 2024

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

January 16, 2024

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

December 27, 2023

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

December 12, 2023

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

November 8, 2023

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

October 26, 2023

CytoSorbents to Present at the 8th Annual Dawson James Conference

October 4, 2023

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

September 26, 2023

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

September 18, 2023

CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation

September 10, 2023

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico

August 31, 2023

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

August 30, 2023

CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial

August 13, 2023

CytoSorbents Reports Second Quarter 2023 Financial and Operational Results

July 31, 2023

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

July 25, 2023

CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer

July 18, 2023

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

July 10, 2023

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

July 6, 2023

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

June 14, 2023

CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference

June 4, 2023

CytoSorbents Reports First Quarter 2023 Results

May 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 77 decks. Every deck is listed under its year.